| Document |
Document Title |
|
WO/2018/183261A1 |
The present invention relates to a compound of Formula (I): where ℗ R, R1, R2, R3, and Z are as described herein and to a process for preparing a compound of Formula (I). This invention also relates to a process for the synthesis of a ...
|
|
WO/2018/177836A1 |
The invention relates to N-cyclopropyl-2-oxopyrrolidine-3-carboxamide derivatives and related compounds of general formula (I) as herbicidal plant protection agents, in particular for controlling weeds and/or weed grasses in crops of use...
|
|
WO/2018/178936A1 |
The application is drawn to radiolabeled biomolecules and methods for radiolabeling biomolecules with radioactive halogen atoms that minimizes loss of the radioactive halogen due to dehalogenation in vivo, preserves the biological activi...
|
|
WO/2018/177861A1 |
The present invention relates to tris-aryl-amide derivatives having an anti-heparanase activity, in particular it relates toureido/thioureido/ether tris-aryl-amide derivatives of formula (I). The invention also relates to the use of such...
|
|
WO/2018/179239A1 |
Provided is a distilling apparatus which enables on-site recycling of spent NMP recovered from, for example, a process of manufacturing electrodes for lithium-ion secondary batteries, and is capable of simply and safely refining the NMP ...
|
|
WO/2018/177863A1 |
The present invention relates to ureido derivatives of naphtalenesulfonic acids having an anti-heparanase activity. In particular, it relates to compounds of formula (I), (I) wherein the meanings of the substituent are specified in the d...
|
|
WO/2018/176134A1 |
The present disclosure relates to compounds for use as electrode additives or as salts in electrolyte compositions, and their methods of preparation. The majority of compounds are anions of imidazoles bearing a sulphonyl or a carbonyl gr...
|
|
WO/2018/178014A1 |
Described are substituted pyrrolidinones of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the gr...
|
|
WO/2018/172423A1 |
The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p¸ q, L, ׇ, X and m are as defined herein. The compound...
|
|
WO/2018/175226A1 |
This application is directed to a compound of Formula II Also disclosed is a process for preparing a compound of Formula II comprising using the compounds of Formulae IV and V Also disclosed is a method for preparing a compound of Formul...
|
|
WO/2018/175449A1 |
The present invention relates to proline amide compounds and their azetidine derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition c...
|
|
WO/2018/174283A1 |
Provided is a sustained-release formulation of evocalcet or a pharmacologically acceptable salt thereof. A polyethylene glycol derivative of evocalcet or a pharmacologically acceptable salt thereof is used.
|
|
WO/2018/169818A1 |
The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological di...
|
|
WO/2018/166819A1 |
The invention relates to a process for the production of compounds of formula (I), comprising Step A of reacting compounds of formula (II) with 2,3-dihalopropionitrile or 2-haloacrylonitrile in the presence of DIPEA. It also relates to a...
|
|
WO/2018/167776A1 |
The present application provides novel process for the preparation of glycopyrrolate tosylate.
|
|
WO/2018/170371A1 |
Provided herein are novel polyaromatic compounds which, upon cure, produce high refractive index polymers. In accordance with certain aspects of the present invention, there are provided high refractive index formulations containing the ...
|
|
WO/2018/164191A1 |
The present invention provides a substituted pyrrolidine compound having orexin receptor type 2 agonist activity. A compound represented by the formula (in the formula, each symbol is as described in the specification) or a salt thereof ...
|
|
WO/2018/164192A1 |
The present invention provides a substituted pyrrolidine compound having orexin-2 receptor agonistic activity. A compound represented by formula (I) (wherein the symbols are as described in the description) or a salt thereof has orexin-2...
|
|
WO/2018/159459A1 |
Provided is a diarylamine-based compound represented by a general formula (1) (in general formula (1), A1 and A2 each independently represent an arylene group which has 6-18 carbon atoms and may have a substituent, and A3 and A4 each ind...
|
|
WO/2018/154597A1 |
Provided herein are processes for preparation of glycopyrronium bromide comprising reaction of N-methylpyrrolidin-3-ol with compounds of Formula I or Formula II followed by additional steps.
|
|
WO/2018/153820A1 |
The invention relates to a novel process for the preparation of a chiral pyrollidine-2-yl-methanol derivative or a salt thereof of the formula (I), wherein R1 is aryl or heteroaryl and both aryl or heteroaryl are optionally substituted b...
|
|
WO/2018/152950A1 |
Provided is a method for preparing brivaracetam, comprising using optically pure (R)-4-n-propyl-dihydrofuran-2(3H)-one as the raw material, and subjecting same to steps such as ring opening, halogenation, condensation and ring closure to...
|
|
WO/2018/152134A1 |
Neuropeptide FF receptor modulators based on a proline scaffold are provided which offer NPFF receptor potencies in the nanomolar range and antagonistic selectivity for the NPFF 1 receptor. Methods, compounds and compositions for modulat...
|
|
WO/2018/150906A1 |
This liquid crystal display device 10 is provided with: a pair of substrates which have conductive films 14, 15, respectively; a liquid crystal layer 12 which is arranged between the pair of substrates and contains liquid crystals; and a...
|
|
WO/2018/147292A1 |
The present invention addresses the problem of providing a novel plant growth suppression agent and a plant growth suppression method that uses the same. This plant growth suppression agent includes, as an active ingredient, a compound e...
|
|
WO/2018/147290A1 |
The present invention addresses the problem of providing a novel plant growth suppression agent and a plant growth suppression method that uses the same. This plant growth suppression agent includes, as an active ingredient, at least one...
|
|
WO/2018/141276A1 |
Disclosed are a novel crystal form of a brivaracetam intermediate compound (I) and preparation method thereof, and a novel crystal form of brivaracetam and preparation method thereof, specifically a crystal form A of a compound I and a c...
|
|
WO/2018/140512A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...
|
|
WO/2018/139438A1 |
[Problem] To provide a compound useful as a cathepsin S inhibitor. [Solution] The present inventors have studied on a compound which has a cathepsin S-inhibiting activity and can be used as an active ingredient for a pharmaceutical compo...
|
|
WO/2018/133846A1 |
The present invention relates to a cyclothiourea compound and the use thereof. In particular, disclosed in the present invention are a compound having the structure as shown in formula (A) which can be used as an HBV replication inhibito...
|
|
WO/2018/130063A1 |
The present invention provides an (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, which has diffraction peaks when 2θ is 12.423±0.2°, 16.465±0.2°, 17.344±0.2°, 21.889±0.2°, and 25.054±0.2°. The present invention can p...
|
|
WO/2018/130062A1 |
The present invention provides a method for preparing an (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, which has diffraction peaks when 2θ is 12.423±0.2°, 16.465±0.2°, 17.344±0.2°, 21.889±0.2°, and 25.054±0.2°. The ...
|
|
WO/2018/131657A1 |
The present invention provides a method by which a dinitro compound that is a precursor of a diamine compound which serves as a production starting material for a polyamic acid and/or a polyimide is produced with high purity and high yie...
|
|
WO/2018/129552A1 |
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...
|
|
WO/2018/124453A1 |
The present invention relates to a method for producing an N-substituted maleimide using a heterogeneous solid acid catalyst. Specifically, the purpose of the present invention is to provide a method for producing an N-substituted maleim...
|
|
WO/2018/121689A1 |
The present invention provides a sulfonamide-aryl amide compound and a use thereof as a drug for treating hepatitis B. Particularly, the present invention provides a compound as an HBV replication inhibitor and having the structure shown...
|
|
WO/2018/124140A1 |
Provided are: a method for producing a diamine compound represented by formula (1), the method comprising a step of reacting the bismaleimide compound represented by formula (A) with either a diamino compound in which P1 in the compound ...
|
|
WO/2018/115421A1 |
The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
|
|
WO/2018/119108A1 |
The present invention relates to solid, oral dosage forms of asimadoline comprising lactose monohydrate.
|
|
WO/2018/118384A1 |
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein R1, R2, R3, R4, R5, R6, J2, Q1, Q2, T and Y are as defined in the disclosure. Also disclosed are compositions containing the compound...
|
|
WO/2018/111803A1 |
The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present inventio...
|
|
WO/2018/109192A1 |
The present invention relates to novel cationic azomethine direct dyes of formula (I) and the leuco forms thereof of formula (II), and also to the use thereof for dyeing keratin fibres, in particular human keratin fibres such as the hair...
|
|
WO/2018/107167A1 |
This present disclosure is directed to compounds of formula (I): (I) where R1a, R1b, R1c, R1d, R1e, R3, R4a, R4b, R4c, R4d, R6, R7, and R8 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically...
|
|
WO/2018/104856A1 |
A process of obtaining a purified geometric isomer of an unsaturated macrocyclic compound is disclosed herein. The process is effected by contacting an ion exchange medium comprising silver ions with a mixture comprising at least one geo...
|
|
WO/2018/104307A1 |
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...
|
|
WO/2018/104305A1 |
Substituted aromatic sulfonamides of formula (I) which are antagonists or negative allosteric modulators of P2X4, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a ph...
|
|
WO/2018/107072A1 |
Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result fro...
|
|
WO/2018/102252A1 |
Described herein are bacteriochlorins comprising an annulated isocyclic ring. Also described are methods and intermediates for the synthesis of bacteriochlorins comprising an annulated isocyclic ring, and methods of using such bacterioch...
|
|
WO/2018/098781A1 |
The present invention provides compounds which are of the formula (I) and (II), wherein X is selected from the group consisting formula (III), (IV), (V) and (VI); R is selected from the group consisting of formula (VII), (VIII), (IX), (X...
|
|
WO/2018/102419A1 |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
|
